Pulling SEC filings + quote and writing the call…
SRPT
Sarepta Therapeutics, Inc.
Next earnings Aug 4, 2026 (after close) · consensus $0.23 EPS, $375M rev
Last earnings +5.7% on 2026-05-06
$17.65
▲ +0.68%$17.53▼ -16.28%
over 1Y
L $11.93EODHDH $24.45
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today+0.7%
1W+16.9%
1M+5.3%
3M+5.3%
YTD-17.7%
1Y-16.3%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 33 analysts
Hold
Unprofitable (net margin -38.3%).
Sarepta Therapeutics, Inc. shows $1.86B in FY2025 revenue (+4.3% YoY), a -38.3% net margin, and -62.5% ROE.
Sources: SEC EDGAR (CIK 0000873303, latest 10-Q filed 2026-05-06) · EODHD · as of 6/22/2026, 3:24:26 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.